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Background
Bevacizumab is a humanized monoclonal antibody devel-
oped against vascular endothelial growth factor (VEGF)
for the treatment of metastatic colorectal cancer (MCRC).
The changes and correlations of sTRAIL and CXCL8
prior to treatment and three months following therapy as
well as the corresponding Positron emission tomography
(18FDG-PET/CT) results were evaluated.
Methods
The measurements were taken before and after treatment
for comparison purposes. The study population com-
prised 17/29 patients with MCRC, undergoing PET/CT
scanning prior to treatment. We were able to perform a
follow up PET/CT examination three months after onset
of therapy in 15/17 patients.Patients were instructed to
fast for at least 6h before an injection of 18F-FDG
(5 MBq/kg)(GeminiPET/CTsystem). Images were recon-
structed using the maximum-likelihood 3-dimensional
algorithm according to standard clinical protocol: 2 itera-
tions,relaxation parameter of 0.05,5-mm,3-dimensional
gaussian postfiltering, a4·4·4mm-voxel grid sampling, and
attenuation correction based on a low-dose CT scan.All
images were visually interpreted by consensus between
two experienced nuclear physicians and standardized
uptake values(SUVmax) were calculated from the image
data.
Results
There were significant changes prior to treatment and
three months later for sTRAIL(p=0.0080) and CXCL8
(p=0.0001). Generally, sTRAIL values were increasing
during therapy, while a decrease was observed for
CXCL8. Correlation analysis was applied to the data and
revealed significant correlations for the SUVmax in the
primary tumor prior to treatment and CXCL8 prior to
therapy (p=0.0303). Furthermore, significant correlations
were observed for the SUVmax and sTRAIL(p=0.0237) as
well as CXCL8(p=0.0002) three months after treatment
initiation. CXCL8 prior to treatment was also correlated
with the SUV three months after onset of treatment
(p=0.0072). A significant correlation was noted for one
combination of two variables, the SUVmax in the metas-
tases and CXCL8 prior to treatment (p=0.0175). These
results are supported when we group the SUVmax in the
metastases following treatment into two groups with
SUVmax<5 and SUVmax>5. There is a significant differ-
ence for both groups regarding overall survival, with a
lower survival associated with SUVmaxs exceeding.
Conclusions
This study provides evidence that proteomics patterns of
sTRAIL and CXCL8 predict tumor response und survival
in MCRC patients treated with bevacizumab and within a
high concordance of 18-FDG-PET/CT findings. The high
correlation of CXCL8 and FDG uptake in metastases prior
to treatment with survival direct to a promising approach
to individualize treatment of patients.
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